Open Access

Diagnostic evaluation and short-term outcome as indicators of long-term prognosis in horses with findings suggestive of inflammatory bowel disease treated with corticosteroids and anthelmintics

  • Ritva Kaikkonen1, 4,
  • Kati Niinistö1Email author,
  • Benjamin Sykes2,
  • Marjukka Anttila3,
  • Satu Sankari1 and
  • Marja Raekallio1
Acta Veterinaria Scandinavica201456:35

https://doi.org/10.1186/1751-0147-56-35

Received: 13 November 2013

Accepted: 26 May 2014

Published: 3 June 2014

Abstract

Background

Recurrent colic and unexplained weight loss despite good appetite and adequate feeding and management practices are common conditions in the horse. However, little information has been published on the systematic diagnostic evaluation, response to treatment, prognostic factors or outcome of either presentation. The aims of this study were to 1) identify possible prognostic indicators and 2) report the short- and long-term response to treatment with corticosteroid therapy of a variety of horses with a presumptive diagnosis of inflammatory bowel disease (IBD).

Thirty-six horses with a history of recurrent colic and/or unexplained weight loss were screened with a detailed clinical, clinicopathological and diagnostic imaging examination. Twenty horses were subsequently selected that had findings consistent with inflammatory bowel disease based on the fulfilment of one or more of the following additional inclusion criteria: hypoproteinaemia, hypoalbuminaemia, malabsorption, an increased intestinal wall thickness on ultrasonographic examination or histopathological changes in rectal biopsy. These 20 horses were treated with a standardized larvicidal anthelmintic regime and a minimum of three weeks of corticosteroid therapy.

Results

The initial response to treatment was good in 75% (15/20) of horses, with a 3-year survival rate of 65% (13/20). The overall 3-year survival in horses that responded to initial treatment (12/15) was significantly higher (P = 0.031) than in those that did not respond to initial treatment (1/5). The peak xylose concentration was significantly (P = 0.048) higher in survivors (1.36 ± 0.44 mmol/L) than non-survivors (0.94 ± 0.36 mmol/L).

Conclusions

The overall prognosis for long-term survival in horses with a presumptive diagnosis of IBD appears to be fair to moderate, and the initial response to anthelmintic and corticosteroid therapy could be a useful prognostic indicator. The findings of the present study suggest that a low peak xylose concentration in absorption testing is associated with a less favourable prognosis, supporting the use of this test.

Keywords

Horse Weight loss Colic IBD Total protein Albumin D-xylose

Background

Recurrent colic and weight loss are conditions in the horse that can present either in combination or as separate problems. Numerous reasons exist for both presentations, including management and feeding practices, intestinal diseases such as parasitism and neoplasias[1, 2] and various non-intestinal diseases[1]. Inflammatory bowel disease (IBD) is another potential cause of both recurrent colic and weight loss that has been histologically classified into the different subtypes of lymphocytic-plasmacytic enterocolitis (LPE), granulomatous enteritis (GE), multisystemic eosinophilic epitheliotropic disease (MEED), diffuse eosinophilic enteritis (DEE) and idiopathic focal eosinophilic enteritis (IFEE)[36]. IBD has previously been reported to cause a variety of clinical presentations, from malabsorption and weight loss to diarrhoea and colic. In particular, eosinophilic enteritis has been reported to cause colic, while weight loss, hypoproteinaemia, hypoalbuminaemia and carbohydrate malabsorption have all been associated with LPE, MEED and GE[4, 5].

Currently, diagnostic evaluation of equine gastrointestinal disease includes clinical and dental examination, routine haematology and biochemistry. Where these fail to identify the pathology, abdominal ultrasonography, carbohydrate absorption tests and histopathology of rectal mucosal biopsies may be useful[1]. The use of rectal mucosal biopsies is appealing, as they are minimally invasive and easy to obtain with no specialized equipment, and histopathology has been demonstrated to be potentially useful in determining the underlying disease process[7, 8]. Alternatively, gastric and duodenal mucosal biopsies can be taken via endoscopy, or full thickness intestinal biopsies can be taken via exploratory celiotomy. However, these require specialized equipment that is not always available or affordable, which limits their usefulness.

Indirect tests of intestinal function, such as D-xylose and glucose absorption, have been described in the horse. These tests can provide useful information, particularly on small intestinal function. The D-xylose absorption test is considered more accurate than the glucose absorption test, because D-xylose is not normally present in the horse and the serum concentration of D-xylose is not affected by factors such as metabolic status, stress or excitement, in contrast to glucose[1, 913].

The retrospective evaluation of horses with weight loss has recently been reported by Metcalfe et al.[14], but at present there is a paucity of systematic prospective studies evaluating the results, and identification of risk factors, from routine examination (history and clinical evaluation), measurement of carbohydrate absorption, abdominal ultrasonography and histopathological findings from rectal biopsy in horses with recurrent colic or weight loss. Furthermore, limited information exists regarding the treatment response of various enteropathies to corticosteroid therapy, although the prognosis of IBD is generally regarded as guarded to poor[4, 8, 1517]. Finally, the long-term prognosis for horses with a presumptive diagnosis of IBD that respond to initial treatment with corticosteroid therapy has not yet been reported.

The aims of the study were to 1) identify prognostic indicators and 2) report the short- and long-term response of a variety of horses with signs suggestive of IBD to treatment with corticosteroid and anthelmintic therapy.

Methods

Horses

The prospective cohort clinical study was performed between 1 May 2004 and 31 December 2005 at the Equine Hospital of the Faculty of Veterinary Medicine, University of Helsinki, and Hyvinkää Equine Hospital, Finland. Long-term survival was reported for a 3-year period following the discontinuation of treatment. Horses with a history of recurrent colic, as defined by at least two episodes of colic requiring veterinary attention during the preceding 12 months[18], or anamnestic information regarding unexplained weight loss or an inability to gain weight despite adequate feeding and management practices, were considered eligible for initial screening for inclusion in the study. Furthermore, to be eligible for screening, horses were required to be ≥2 years of age and have received adequate feeding, deworming and dental care as determined by the examining veterinarian. Horses that presented with acute colic or that had previously undergone colic surgery were excluded, as were horses receiving corticosteroid therapy at the time of assessment or in the six months preceding assessment. The study was approved by the Ethical Committee of the University of Helsinki (UH number 89–04). Informed consent from the owner, or the trainer acting as an agent for the owner, was obtained at the time of enrolment in the study.

Diagnostic evaluation

A thorough history was obtained, including signalment and management. The initial examination included a basic clinical examination, determination of body weight with scales, lameness examination, oral examination, palpation per rectum, a complete blood count, fibrinogen measurement, serum biochemistry (globulins were counted by subtracting serum albumin from total protein), thoracic and abdominal radiography, transabdominal ultrasonography, peritoneal fluid analysis, urinalysis, a faecal flotation test for parasites, a D-xylose absorption test[19], gastroscopy and duodenoscopy[20], as well as a rectal mucosal biopsy and histopathology, as described by Lindberg et al.[7]. The body condition score was determined by two clinicians, as described by Henneke et al.[21], and ranged from 1 to 9, where 1 was extremely emaciated and 9 extremely overweight.

In addition to having fulfilled the criteria for initial screening to be included in the final study, horses had to fulfil at least one of the following criteria: hypoproteinaemia (defined as a serum total protein concentration of less than 54 g/L), hypoalbuminaemia (defined as a serum albumin concentration of less than 28 g/L), a peak plasma xylose concentration of less than 1.33 mmol/L[1], increased intestinal wall thickness (>4 mm) according to ultrasonographic assessment[22] or changes in the rectal mucosal biopsy suggestive of IBD. Horses were excluded from the final study if another, non-IBD cause of the presenting clinical signs was identified. This included horses with significant intestinal sand accumulation[23], severe gastric ulceration (grades 3–4/4), evidence of infectious disease as indicated by changes in haematology and/or fibrinogen, and serum biochemical changes consistent with renal or hepatic failure.

Therapeutic protocols

All horses included in the study were initially treated with the same protocol. Anthelmintics were started with five consecutive days of fenbendazole (Axilur, MSD Animal Health) 10 mg/kg per os (PO) once daily, followed by a single dose of ivermectin at 0.2 mg/kg and praziquantel at 1 mg/kg (Equimax, Virbac de Portugal) PO on day 6. Prednisolone (Prednisolon 40 mg, Leiras) at 1 mg/kg PO once daily was started on day 1 and continued until the first follow-up examination was performed, after approximately three weeks of treatment.

On follow-up, the horses were clinically evaluated, body weight was determined by scales, and the tests previously identified as abnormal were repeated. Further medication was decided at the treating clinician’s discretion according to the findings from the follow-up examination and based on the following guidelines: if the original complaint(s) (weight loss and/or recurrent colic) had clinically improved and the results from any/all previously abnormal tests (D-xylose absorption, histopathology of rectal mucosal biopsy, intestinal wall thickness as determined by ultrasonography, hypoalbuminaemia and/or hypoglobulinaemia) had improved or normalised, corticosteroid therapy was gradually tapered and then discontinued. Horses that had shown minimal or no improvement were changed to dexamethasone (Dexametason 1.5 mg, Orion Pharma) at 0.1 mg/kg PO once daily with subsequent treatment at the treating clinician’s discretion. Horse owners were interviewed by telephone about their horse’s condition and the possible reoccurrence of any symptoms approximately 3 and 6 months following the discontinuation of treatment. The national horse register database was used to trace horses for long-term survival at three years after the discontinuation of treatment.

Statistical analysis

The Shapiro-Wilk test was used to evaluate whether the data were normally distributed. Pearson correlations were calculated between the normally distributed parameters, and the two-tailed Student’s t-test was used for comparisons between horses that were or were not alive three years after treatment. Spearman's correlation and the Mann–Whitney U-test were used for nonparametric data. A two-tailed Fischer’s exact test was used to compare the response to initial treatment between survivors and non-survivors. Significance was set at P < 0.05. Post-hoc power calculations were performed using online data management software[24].

Results

Horses

Thirty-six client-owned horses met the criteria for initial screening, with 20 horses subsequently included in the final study. Five of the 20 horses included in the final study had a primary complaint of recurrent colic, nine horses were included due to weight loss and six presented with a history of both recurrent colic and weight loss.

Diagnostic evaluation

Histopathology of the rectal mucosal biopsy was considered abnormal in 5/13 and 3/7 of survivors and non-survivors, respectively. Intestinal thickening (>4 mm), as determined by ultrasound, was present in 6/13 and 4/7 of survivors and non-survivors, respectively. These proportions did not significantly differ between survivors and non-survivors. The proportion of horses with a peak D-xylose concentration below the normal threshold of 1.33 mmol/L did not differ between survivors (8/13) and non-survivors (6/7). However, the mean peak D-xylose concentration was significantly higher in survivors (1.36 ± 0.44) than non-survivors (0.94 ± 0.36) (P = 0.048). Faecal flotation was negative in all horses. The presumptive diagnosis of the IBD subtype was based on the history, clinical presentation and the results of the diagnostic work-up, with particular emphasis placed on histopathological changes in the rectal mucosal biopsy.

Treatment and follow up

Treatment was attempted in all horses and all returned for re-evaluation at approximately three weeks. Five horses failed to demonstrate satisfactory improvement in their clinical or clinicopathological parameters in the first weeks and were changed to dexamethasone therapy as outlined above. The remaining 15 horses were considered to have improved and corticosteroid therapy was tapered and discontinued.

Seven of the 20 horses died during the three-year follow-up period, with death related to the original problem of weight loss or recurrent colic in all but one horse (Table 1). Of these seven horses, three had initially responded well to treatment, while four had responded poorly. The overall 3-year survival rate in horses that responded to initial treatment (12/15: 80%) was significantly higher (P = 0.031) than in horses that did not respond to initial treatment and were subsequently changed to dexamethasone (1/5: 20%). Five of the non-surviving horses underwent post-mortem examination, and in four of these horses this examination confirmed the presumptive diagnosis of inflammatory bowel disease. Table 2 presents the age, body composition score, serum protein, albumin and globulin concentration, and peak D-xylose concentrations at enrolment, as well as the length of treatment for survivors and non-survivors. The peak D-xylose concentration correlated significantly with serum total protein (r = 0.45, P < 0.001) and globulin concentrations (r = 0.61, P = 0.005), but not with serum albumin concentration (r = −0.19, P = 0.41). The power of the study to detect a difference between survivors and non-survivors was 49.1%, 12.1% and 62.6% for serum total protein, serum albumin and serum globulin concentrations, respectively.
Table 1

Presumptive IBD subtype (based on the clinical picture and findings from the diagnostic work-up) and post-mortem diagnoses (when available) of non-survivors (n = 7), and length of survival after the discontinuation of treatment

Presumptive diagnosis

Time when died/euthanized

Indication

Post-mortem diagnosis

Lymphocytic-plasmacytic enteritis

During the treatment (day 26)

Progressive weight loss, animal welfare

Lymphocytic-plasmacytic enteritis

Eosinophilic enterocolitis

2 days after discontinuing the treatment

Colic

Idiopathic small intestinal muscular hypertrophy

Eosinophilic enterocolitis

22 days after discontinuing the treatment

Death due to acute cardiac failure

Eosinophilic enterocolitis Acute cardiac failure

Eosinophilic enterocolitis

30 days after discontinuing the treatment

Colic

Not performed

Lymphocytic-plasmacytic enteritis

120 days after discontinuing the treatment

Progressive weight loss

Lymphocytic-plasmacytic enteritis

Eosinophilic enterocolitis

7 months 13 days after discontinuing the treatment

Recurrent colic

Not performed

Eosinophilic enterocolitis

1 year 8 months after discontinuing the treatment

Recurrent colic

Eosinophilic enterocolitis

Table 2

Means ± SD (min–max) of the age, body composition score, serum protein, albumin and globulin concentrations, and peak xylose concentration, the numbers of horses with each abnormal finding and the length of treatment in long-term (3 years) survivors and non-surviving horses

 

Survivors (n = 13)

Non-survivors (n = 7)

P

Age (years)

9.7 ± 4.5 (3–17)

10.0 ± 5.3 (4–20)

0.893

Body score

3.9 ± 1.4 (2–7)1

3.6 ± 0.5 (3–4)

0.598

S-protein (g/L)

61.6 ± 8.3 (44.2–77.2)

53.4 ± 11.9 (30.6–69.6)

0.086

S-albumin (g/L)

33.1 ± 5.5 (20.3–40.8)

31.4 ± 8.7 (14.7–39.4)

0.843

S-globulin (g/L)

28.5 ± 7.5 (21.3–46.4)

22.0 ± 6.8 (15.5–30.9)

0.073

Peak xylose (mmol/L)

1.36 ± 0.44 (0.85–2.27)

0.94 ± 0.36 (0.27–1.37)

0.048

Length of treatment (d)

51.1 ± 13.2 (22–69)

71.1 ± 32.8 (43–120)2

0.065

1Data missing from two surviving horses.

2One horse is not included in this calculation as it was euthanized on humane grounds after 26 days of treatment.

Discussion

In the present study, the response to anthelmintic and corticosteroid therapy over a three-week period was demonstrated to be a useful predictor of the outcome in horses with a presumptive diagnosis of IBD. The long-term prognosis for horses in the present study was fair to moderate, with 65% of the horses surviving at least three years. This is in contrast to the current literature, in which the response of IBD to corticosteroid treatment is generally considered to be poor[4, 8, 16, 17]. Possible reasons for this discrepancy, including case selection, case definition and the role of anthelmintic therapy in the outcome, warrant discussion.

Anthelmintic therapy was performed regardless of the negative results of faecal analysis, as the faecal flotation test underestimates the parasite burden when there are more larval stages than adults, and is unable to detect encysted cyathostomes[25]. Furthermore, it has been postulated that endoparasites may have a role in triggering the disease process of inflammatory bowel disease[2628]. As such, the treatment of endoparasitism in suspected IBD cases is logical. Fenbendazole was chosen as the therapeutic agent, as it is efficacious against encysted cyathostomes when used as described above[29], and there was no known resistance towards fenbendazole in the geographical area in which the study was performed.

Although both hospitals involved in the study were referral centres, the case load at both facilities is a broad representation of the clinical spectrum, with a large proportion of the case load effectively comprising first opinion cases. The inclusion of first opinion cases may at least partly explain the better outcome observed in the study than previously reported. Similarly, most of the cases in the present study that were presumptively diagnosed with IBD were less severely affected than the confirmed cases described in the literature[8, 30, 31]. This may have biased the population studied towards animals that were more likely to respond to treatment than those previously reported from true referral populations[4, 8, 16, 17]. Alternatively, it is possible that the response to treatment seen in some cases was due to the larvicidal anthelmintic treatment that was included in the protocol rather than the corticosteroids. All horses in the present study had a history of adequate anthelmintic treatment, and no significant parasite burdens were detected on faecal analysis, reducing the likelihood that endoparasites were a major factor. However, neither factor excludes parasitism as a potential diagnosis, especially cyathostomiasis, as discussed above.

The authors recognise that the definition of IBD used in this study is broad and may inadvertently encompass other disease conditions such as low-grade cyathostomiasis. However, despite the limitations in ruling out parasitism and achieving a definitive diagnosis, we believe that present study accurately reflects the clinical presentation of weight loss and recurrent colic seen in practice. As such, we argue that the results of the study are applicable to the clinical setting. The finding that the response to initial treatment is predictive of long-term survival is of particular importance and direct clinical relevance. The development of clearer guidelines for the diagnosis of IBD would be beneficial in defining inclusion criteria for future prospective studies.

The results of this study support the use of the D-xylose test in the diagnostic evaluation of recurrent colic and weight loss, with inadequate D-xylose absorption the only significant clinicopathological prognosticator of survival identified. Importantly, the horse’s diet can influence the D-xylose curve, with horses fed a high-energy diet reported to have lower peak plasma concentrations[32]. Additionally, prolonged fasting (72–96 h) can lower the peak concentration of D-xylose[33] and warrants consideration in the interpretation of the test results. In the present study, all the horses were fed in a similar manner, with none receiving a high-energy diet, and no horses were fasted for a prolonged period before testing. As such, these factors are unlikely to have influenced the accuracy of the test.

In the present study, peak D-xylose concentrations were not associated with the serum albumin concentration, but were associated with the serum globulin concentration. This contradicts the existing literature, wherein it is commonly assumed that horses with malabsorption will also have a low serum albumin concentration, since the rate of albumin production is slower compared to globulin production[34]. This assumption is supported by a recent study in which both hypoproteinaemia and hypoalbuminaemia, but not hypogammaglobulinaemia, were associated with non-survival in horses with unexplained weight loss[14]. The small number of horses in the present study is a significant limitation, and the power of the study to detect a difference between survivors was only 49.1%, 12.1% and 62.6% for serum total protein, serum albumin and serum globulin concentrations, respectively. As such, the risk of a type II error was relatively high in the present study. The trend towards a difference between survivors and non-survivors in serum total protein, which is consistent with a recent report[14], and in serum globulins, which has not previously been reported, warrants consideration in the interpretation of results, although care should be taken in drawing firm conclusions.

Interestingly, despite hypoalbuminaemia previously being identified as a significant risk factor for non-survival in a previous study[14], the data from the present study do not support a similar conclusion. The reasons for this discrepancy are not immediately apparent. Both the present study and the previous study by Metcalfe et al.[14] reporting the outcome of chronic gastrointestinal disease were limited by small numbers. The risk of both type I and type II statistical errors increases as a function of decreasing sample size, and consequentially power[35]. As such, the inability to find an association between serum albumin and the outcome in the present study, or the association previously reported by Metcalfe et al.[14], could be erroneous due to a type II or type I statistical error, respectively. Considering this, a larger prospective clinical study is warranted to further investigate the relationship between clinicopathological parameters and the outcome before any firm conclusions can be drawn. However, combining the results of the present study with the previous observations of Metcalfe et al.[14], serum total protein appears to be the most consistent clinicopathological predictor of the outcome.

Histopathological changes in the rectal biopsy were detected in less than half of the cases studied, but the findings of the present study suggest that when present, changes in rectal mucosal histopathology were in line with subsequent post-mortem findings. This supports their use in the diagnostic evaluation of weight loss and/or recurrent colic cases.

Conclusions

The overall prognosis for long-term survival in horses with a presumptive diagnosis of IBD appears to be fair to moderate. The initial response to anthelmintic and corticosteroid therapy could be a useful prognostic indicator, and the findings of the present study suggest that a low peak xylose concentration in absorption testing is associated with a less favourable prognosis, supporting the use of this test.

Declarations

Acknowledgements

This study was partly supported by a grant from the Orion-Farmos Research Foundation. We would also like to acknowledge Orion Pharma for providing the ivermectin/praziquantel preparation and Intervet (currently MSD Animal Health) for providing the fenbendazole preparation.

Authors’ Affiliations

(1)
Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki
(2)
Faculty of Veterinary Medicine, Estonian University of Life Sciences
(3)
Pathology Unit, EVIRA
(4)
Animagi Equine Clinic Oulu

References

  1. Tamzali Y: Chronic weight loss syndrome in the horse: a 60 case retrospective study. Equine Vet Educ. 2006, 18: 372-380.Google Scholar
  2. Taylor SD, Pusterla N, Vaughan B, Whitcomb MB, Wilson WD: Intestinal neoplasia in horses. J Vet Intern Med. 2006, 20: 1429-1436. 10.1111/j.1939-1676.2006.tb00762.x.View ArticlePubMedGoogle Scholar
  3. Edwards GB, Kelly DF, Proudman CJ: Segmental eosinophilic colitis: a review of 22 cases. Equine Vet J Suppl. 2000, 32: 86-93. 10.2746/042516400777612017.View ArticlePubMedGoogle Scholar
  4. Schumacher J, Edwards JF, Cohen N: Chronic idiopathic inflammatory bowel diseases of the horse. J Vet Intern Med. 2000, 14: 258-265. 10.1111/j.1939-1676.2000.tb01164.x.View ArticlePubMedGoogle Scholar
  5. Archer DC, Edwards GB, Kelly DF, French NP, Proudman CJ: Obstruction of equine small intestine associated with focal idiopathic eosinophilic enteritis: An emerging disease?. Vet J. 2006, 171: 504-512. 10.1016/j.tvjl.2005.02.031.View ArticlePubMedGoogle Scholar
  6. Perez Olmos JF, Schofield WL, Dillon H, Sadlier M, Fogarty U: Circumferential mural bands in the small intestine causing simple obstructive colic: a case series. Equine Vet J. 2006, 38: 354-359. 10.1111/j.2042-3306.2006.tb05568.x.View ArticlePubMedGoogle Scholar
  7. Lindberg R, Nygren A, Persson SGB: Rectal biopsy diagnosis in horses with clinical signs of intestinal disorders; a retrospective study of 116 cases. Equine Vet J. 1996, 28: 275-284. 10.1111/j.2042-3306.1996.tb03091.x.View ArticlePubMedGoogle Scholar
  8. Kemper DL, Perkins GA, Schumacher J, Edwards JF, Valentine BA, Divers TJ, Cohen ND: Equine lymphocytic-plasmacytic enterocolitis: a retrospective study of 14 cases. Equine Vet J Suppl. 2000, 32: 108-112.View ArticlePubMedGoogle Scholar
  9. Roberts MC: The D(+) Xylose absorption test in the horse. Equine Vet J. 1974, 6: 28-30. 10.1111/j.2042-3306.1974.tb03924.x.View ArticlePubMedGoogle Scholar
  10. Bolton JR, Merritt AM, Cimprich RE, Ramberg CF, Streett W: Normal and abnormal xylose absorption in the horse. Cornell Vet. 1976, 66: 183-197.PubMedGoogle Scholar
  11. Mair TS, Hillyer MH, Taylor FGR, Pearson GR: Small intestinal malabsorption in the horse: an assessment of the specificity of the oral glucose tolerance test. Equine Vet J. 1991, 23: 344-346. 10.1111/j.2042-3306.1991.tb03735.x.View ArticlePubMedGoogle Scholar
  12. Brown CM: The diagnostic value of the D-xylose absorption test in horses with unexplained chronic weight loss. Br Vet J. 1992, 148: 41-44. 10.1016/0007-1935(92)90065-9.View ArticlePubMedGoogle Scholar
  13. Mayes PA, Bender DA: Gluconeogenesis and control of blood glucose. Harpers Illustrated Biochemistry. Edited by: Murray RK, Granner DK, Mayes PA, Rodwell VW. 2003, New York: Lange Medical Books/McGraw-Hill, 154-162. 26Google Scholar
  14. Metcalfe LVA, More SJ, Duggan V, Katz LM: A retrospective study of horses investigated for weight loss despite a good appetite (2002–2011). Equine Vet J. 2013, 45: 340-345. 10.1111/j.2042-3306.2012.00624.x.View ArticlePubMedGoogle Scholar
  15. Johnson PJ, Goetz TE: Granulomatous enteritis and Campylobacter bacteremia in a horse. J Am Vet Med Assoc. 1993, 203: 1039-1042.PubMedGoogle Scholar
  16. McCue M, Davis EG, Rush BR, Cox JH, Wilkerson MJ: Dexamethasone for treatment of multisystemic eosinophilic epitheliotropic disease in a horse. J Am Vet Med Assoc. 2003, 223: 1320-1323. 10.2460/javma.2003.223.1320.View ArticlePubMedGoogle Scholar
  17. Stämpfli H, Oliver OE: Chronic diarrhea and weight loss in three horses. Vet Clin North Am Equine Pract. 2006, 22: 27-35. 10.1016/j.cveq.2005.12.029.View ArticleGoogle Scholar
  18. Cohen ND, Peloso JG: Risk factors for history of previous colic and for chronic, intermittent colic in a population of horses. J Am Vet Med Assoc. 1996, 208: 697-703.PubMedGoogle Scholar
  19. Tinder O: Micro-determination of xylose in plasma. Analyst. 1975, 100: 12-15. 10.1039/an9750000012.View ArticleGoogle Scholar
  20. Andrews F, Bernard W, Byars D, Cohen N, Divers T, MacAllister C, McGladdery A, Merrit AM, Murray MJ, Orsini J, Snyder J, Vatistas N: Recommendations for the diagnosis and treatment of equine gastric ulcer syndrome (EGUS). Equine Gastric Ulcer Council. Equine Vet J. 1999, 11: 262-272.Google Scholar
  21. Henneke DR, Potter GD, Kreider JL, Yeates BF: Relationship between condition score, physical measurements and body fat percentage in mares. Equine Vet J. 1983, 15: 371-372. 10.1111/j.2042-3306.1983.tb01826.x.View ArticlePubMedGoogle Scholar
  22. Reef VB: Adult abdominal ultrasonography. Equine Diagnostic Ultrasound. Edited by: Reef VB. 1998, Philadelphia: WB Saunders, 273-364.Google Scholar
  23. Kendall A, Ley C, Egenvall A, Bröjer J: Radiographic parameters for diagnosing sand colic in horses. Acta Vet Scand. 2008, 50: 17-10.1186/1751-0147-50-17.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Knowledge Center/Calculators. Arlington, VA 22201, US: DSS Research,http://www.dssresearch.com/KnowledgeCenter/toolkitcalculators/statisticalpowercalculators.aspx,
  25. Stradford CH, McGorum BC, Pickles KJ, Matthews JB: An update on cyathostomins: Anthelmintic resistance and diagnostic tools. Equine Vet J. 2011, 43: 133-139.View ArticleGoogle Scholar
  26. Roberts MC: Malabsorption syndromes in the horse. Comp Cont Educ Pract Vet. 1985, 7: 637-646.Google Scholar
  27. Cohen ND, Loy JK, Craig TM, McMullan WC: Eosinophilic gastroenteritis with encapsulated nematodes in a horse. J Am Vet Med Assoc. 1992, 200: 1518-1520.PubMedGoogle Scholar
  28. Kalck KA: Inflammatory bowel disease in horses. Vet Clin North Am Equine Pract. 2009, 25: 303-315. 10.1016/j.cveq.2009.04.008.View ArticlePubMedGoogle Scholar
  29. Lyons ET, Drudge JH, Tolliver SC: Larval cyathostomiasis. Vet Clin North Am Equine Pract. 2000, 16: 501-513.PubMedGoogle Scholar
  30. Bassage LH, Johnston JK, Krotec KL: Eosinophilic enterocolitis associated with recurrent colonic impactions in a mare. Equine Vet J. 1997, 29: 322-325. 10.1111/j.2042-3306.1997.tb03131.x.View ArticlePubMedGoogle Scholar
  31. Barr BS: Infiltrative intestinal disease. Vet Clin North Am Equine Pract. 2006, 22: 1-7.View ArticleGoogle Scholar
  32. Jacobs KA, Norman P, Hodgson DRG, Cymbaluk N: Effect of diet on the oral D-xylose absorption test in the horse. Am J Vet Res. 1982, 43: 1856-1858.PubMedGoogle Scholar
  33. Freeman DE, Ferrante PL, Kronfeld DS, Chalupa W: Effect of food deprivation on D-xylose test results in mares. Am J Vet Res. 1989, 50: 1609-1612.PubMedGoogle Scholar
  34. Mair TS, Pearson GR, Divers TJ: Malabsorption syndromes in the horse. Equine Vet Educ. 2006, 18: 299-308.View ArticleGoogle Scholar
  35. Christley RM: Power and error: Increased risk of false positive results in underpowered studies. Open Epidemiol J. 2010, 3: 16-19. 10.2174/1874297101003010016.View ArticleGoogle Scholar

Copyright

© Kaikkonen et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement